Lucid Diagnostics Inc
NASDAQ:LUCD
Lucid Diagnostics Inc
Cost of Revenue
Lucid Diagnostics Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
Cost of Revenue
-$7.1m
|
CAGR 3-Years
-129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cost of Revenue
-$11.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$5.3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$8.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$18.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$2.7B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
What is Lucid Diagnostics Inc's Cost of Revenue?
Cost of Revenue
-7.1m
USD
Based on the financial report for Dec 31, 2024, Lucid Diagnostics Inc's Cost of Revenue amounts to -7.1m USD.
What is Lucid Diagnostics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-129%
Over the last year, the Cost of Revenue growth was -19%. The average annual Cost of Revenue growth rates for Lucid Diagnostics Inc have been -129% over the past three years .
You don't have any saved screeners yet